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Nitric oxide antagonizes the actions of angiotensin II to enhance
tubuloglomerular feedback responsiveness
BRANKO BwM and HEIN A. KooiviANs
Department of Nephrology and Hypertension, University Hospital Utrecht, Utrecht, The Netherlands
Nitric oxide antagonizes the actions of angiotensin H to enhance
tubuloglomerular feedback responsiveness. The present study was de-
signed to investigate whether nitric oxide (NO) antagonizes angiotensin II
(Mg II) in modulating the tubuloglomerular feedback (TGF) system.
Maximum TGF responses were assessed by evaluating stop-flow pressure
(SFP) responses to late proximal perfusion with artificial tubular fluid (40
ni/mm). Peritubular capillary (PTC) infusion of i0 M N'-L-arginine
(NLA) at a rate of 20 nI/mm, and infusion of iO- and 106 M Mg II at
rates that did not decrease SFP under conditions of zero flow to the
macula densa (resting SFP), augmented maximum SFP feedback re-
sponses to 12.0 1.7, 12.1 2.4 and 16.9 3.0 mm Hg, respectively (all
P < 0.01 vs. control response). Combined PTC infusion of NLA and
i0 M Mg II at a rate of 20 nI/mm resulted in decreases in resting SFP
in 7 of the 12 nephrons studied. When the infusion rate was decreased to
15 3 ni/mm, concomitant PTC infusion of NLA and i07 M Mg II was
associated with a tremendous increase in maximum TGF responses (23.8
3.9 mm Hg; P < 0.01 vs. responses during PTC NLA or Aug II) in the
absence of a decrease in resting SFP. During AT1 receptor blockade using
losartan, SFP feedback responses were attenuated to 1.6 0.6mm Hg and
PTC infusion of NLA only augmented TGF responses to 3.8 1.0 mm
Hg. These results strongly suggest that local NO antagonizes Mg II with
respect to the regulation of TGF responsiveness. Disruption of this
balance by NO synthesis inhibition strongly potentiates TGF-independent
and TGF-dependent actions of Mg H on the preglomerular vasculature.
The influence of angiotensin II (Ang II) to enhance tubuloglo-
merular feedback (TGF) responsiveness is well-established [1—3].
Recently, studies have shown that inhibition of nitric oxide
synthase (NOS) also enhances TGF responses [4—7], which
implicates that endogenous nitric oxide (NO) attenuates the TGF
system. In vitro studies have provided support for the hypothesis
that Ang II and NO can interact at the level of the afferent
arteriole. Ito, Johnson and Carretero demonstrated that NLA
enhanced and prolonged the vasoconstrictive effects of Ang II in
isolated afferent arterioles [81. Subsequently, they showed that the
interaction between Ang II and NO primarily occurred in the
afferent and not in the efferent arteriole [9]. Ohishi et a! demon-
strated in the juxtamedullary nephron preparation that the affer-
ent arteriolar vasoconstriction elicited by NLA was attenuated in
kidneys pretreated with the AT1 receptor antagonist losartan or
enalaprilat [10]. These reports suggest that the vasodilator NO
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antagonizes the vasoconstrictor actions of Ang II. In view of these
observations the question arises whether endogenous NO also
antagonizes the modulatory actions of Ang II to enhance TGF
responsiveness.
Experiments by Wilcox et al and from our laboratory indicate
that administration of NOS inhibitors into the peritubular capil-
laries, but also to the proximal tubular lumen can enhance TGF
responses [4, 6]. It can be hypothesized that NOS blockers enter
and affect the macula densa from the luminal site [6]. In view of
the reports indicating high concentrations of Ang II in the
proximal tubular lumen [11, 12], it is conceivable that Ang II could
also act on the macula densa from the luminal site. Interaction of
Mg II and NO with respect to TGF responsiveness could
therefore occur both in the afferent arterioles and within the
macula densa.
The present study was designed to investigate whether NO
opposes Mg II in modulating the TGF system. First, it was
examined whether the increase in TGF responses during peritu-
bular administration of the NOS inhibitor NLA is different under
conditions of normal, increased and decreased Ang II activity.
Second, we explored whether intraluminal application of Mg II
and losartan affect TGF responses, as does intraluminal adminis-
tration of NLA, since that supports the possibility of an interac-
tion between NO and Mg II reaching the macula densa from the
lumen and interacting at this level.
Methods
Animals and preparation for micropuncture
Male Sprague-Dawley rats (225 to 275 g; Harlan-Olac, UK)
were fed normal rat chow (Hope Farms, Woerden, NL) contain-
ing approximately 100 mmollkg sodium or received a low sodium
diet, and had free access to tap water. Sentinel animals were
monitored regularly for infection by nematodes and pathogenic
bacteria as well as antibodies for a large number of rodent viral
pathogens [13] and were consistently negative throughout the
course of the experiments. On the day of the experiment, the
animals were anesthetized with sodium-pentobarbital (60 mg/kg
body wt, i.p.) and placed on a servo-controlled surgical table that
maintained rectal temperature at 37°C. After intubation of the
trachea, a catheter (PE-50) was placed into the left jugular vein
for infusion of solutions and a second catheter (PE-lo) was
introduced for additional anesthetic. The femoral artery was
cannulated with PE-50 tubing to monitor arterial blood pressure
continuously, using a pressure transducer (Statham P23dB) and a
polygraph. The left kidney was then approached by a flank
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incision, freed from surrounding tissue and placed into a plastic
holder. The ureter was cannulated with PE-10 tubing. An agar
wall was formed around the kidney to form a saline well.
All animals received an intravenous 150 mrvi NaC1 solution at a
rate of 20 p1/mm. For animals maintained on the 100 mmol/kg
sodium diet this solution also contained 6% bovine serum albu-
min (BSA; Sigma Chemicals), whereas for the animals receiving
the low sodium diet, the BSA content was only 1% during surgery.
The infusion was started immediately after introducing the jugular
vein catheters. Following surgery, all animals received 150 ifiM
NaCl solution containing 1% BSA at a rate of 20 p1/mm, and a
60-minute equilibration period was observed, before the start of
the experimental protocol. The protocol was approved by the
Utrecht University Board for studies in experimental animals.
Assessment of maximum TGF responses
TGF responses were assessed by evaluating maximum stop-flow
pressure (SFP) feedback responses to increases in late proximal
perfusion rate. A proximal tubule with several surface segments
was localized using a 4 to 6 pm tip diameter micropipette filled
with artificial tubular fluid (ATF), containing 0.2% Fast Green
(Sigma Chemicals). The composition of the ATF was as follows
(in mmol/liter): 135 NaC1, 5 KCI, 10 NaHCO3, 1 MgSO4, 1 CaC12,
1 Na2PO4INaH2PO4 and 4 urea (pH 7.40). A wax block was
inserted upstream of the localization pipette with a hydraulic
microdrive (Effenberger, PfaffinglAttel, Germany) and a 3 to 4
pm tip diameter pressure pipette was introduced in a segment
upstream of the wax block. This pressure pipette was connected to
a servo-null pressure system (Instruments for Physiology and
Medicine, San Diego, CA, USA) for continuous monitoring of
SFP. The localization pipette was then replaced by a 6 to 8 pm tip
diameter perfusion pipette filled with stained (0.2% Fast Green)
isotonic ATF, connected to a microperfusion pump system (Ef-
fenberger, Pfaffing, Germany), with the perfusion rate set at 0
nl/min. Prior to the initiation of the late proximal perfusion, SFP
in the absence of flow to the macula densa, resting SFP, was
recorded for at least one minute. The maximum SFP response was
then obtained at a late proximal perfusion rate of 40 nl/min, and
recovery of the zero-flow SFP was obtained.
Peritubular capillary (PTC) infusion experiments
PTC infusion was applied to avoid systemic changes associated
with the administration of Ang II and of NOS inhibitors. Assess-
ment of control maximum TGF-responses was performed as
described above. A second 5 to 7 pm tip-diameter perfusion
pipette, filled with artificial tubular fluid (ATF), containing 0.2%
Fast Green and the experimental compound, was connected to a
second microperfusion pump system. When a stable recovery of
resting SFP was obtained following the control response, the
perfusion pipette was inserted into a star vessel or a first order
capillary in close vicinity of the pressure pipette and the first
visible distal segment. As described previously [3], a peritubular
infusion was judged satisfactory if the flow resulting from the
infusion covered at least two of the proximal tubular segments of
the nephron under study. The test compound was infused for two
to three minutes before TGF mediated decreases in SFP were
obtained. PTC infusion rates were always kept below 20 nl/min,
because this infusion rate has been shown not to affect local flow
in the capillaries [31.
Protocols
PTC administration of NLA. In the first series of experiments,
maximum TGF-mediated decreases in SFP were obtained prior to
and during PTC infusion of i0 M NGnitroLargmnine (NLA;
Research Biochemicals Incorporated, Natic, MA, USA), dis-
solved in ATF and infused at a rate of 20 nl/min.
Combined PTC infusion of NLA andAng II. In the second series
of experiments, a control maximum TGF response with ATF was
obtained and followed by SFP feedback responses during peritu-
bular infusion of 10—6 or iO M Ang II (Sigma Chemicals), and
during PTC infusion of a solution containing both i0— M Ang II
and io— M NLA. Infusion rates of the 10—6 Ang II solution and
the solution containing both Ang II and NLA were decreased if
the regular infusion rate of 20 nl/min resulted in a decrease in
resting SFP. Late proximal perfusion with ATF was only initiated
if a stable resting SFP was obtained. Infusion rates of the io
Ang II solution were matched with the infusion rates of the
solution containing both NLA and Ang II.
PTC infusion of NLA following systemic losartan administration.
In a third series of experiments, maximum TGF responses prior to
and during peritubular infusion of NLA were obtained by late
proximal perfusion with ATF at 40 nl/min in animals maintained
on a low sodium diet that had received of the AT1 receptor
antagonist, losartan. The experiments were performed in the low
sodium animals, in order to acutely block a stimulated Ang II
system. Losartan was administered intravenously in a dose of 10
mg/kg body wt following surgery. It has been previously shown
that this dose effectively blocks the pressor responses to bolus
injection of 50 ng Ang II, and greatly attenuates TGF-mediated
decreases in SFP [2].
Intraluminal administration of Ang II, losartan and NLA. The
fourth series of experiments explored the possibility that NLA and
Ang II delivered to the proximal tubular lumen could alter TGF
responsiveness. First, maximum TGF-mediated decrease in SFP
in response to late proximal perfusion with ATF were obtained
twice to serve as time-controls. In other nephrons, a control
response with ATF was obtained and the second response was
obtained by late proximal perfusion with ATF containing iO M
NLA. In others nephrons, the late proximal perfusion pipette was
replaced following a control response with a perfusion pipet filled
with ATF containing either iO M or iO M losartan dissolved in
ATF, and a second response was obtained. Finally, the control
response with ATF was followed by a second response with ATF
containing 106 M Ang II (Sigma Chemicals). This concentration
of Ang II was chosen, because it substantially exceeds the
concentrations reported in free-flow proximal tubular fluid collec-
tions [11, 12].
Analysis
TGF responses were evaluated during stabilization of SFP for
at least two minutes. Data were analyzed using analysis of
variance (ANOVA). Post hoc evaluation of the differences was
performed with the least significant difference test. The Mann-
Whitney test was employed for the comparison of the resting SFP
during combined PTC infusion of NLA and Ang II, because this
parameter failed to show a Gaussian distribution. P values less
than 0.05 were considered statistically significant.
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Results
FTC administration of NLA
PTC infusion of NLA at a rate of 20 ni/mm resulted in
significant enhancement of the maximum TGF-mediated decrease
in SFP (Fig. 1; N = 14 nephrons in 8 rats). Resting SFP was 46.9
1.2 mm Hg following the control response and 47.1 1.3 mm
Hg 2 to 3 minutes following the initiation of the PTC NLA
infusion. After recovery from the maximum TGF response during
PTC infusion of NLA, resting SFP was 45.9 1.4 mm Hg.
Combined FTC infusion of NLA and Ang II
As is shown in Figure 2, PTC infusion of 106 M Ang II at an
average rate of 10 2 ni/mm clearly augmented maximum TGF
responses, in the absence of changes in resting SFP. However,
when the 10_6 M Ang II was combined with i0— M NLA, resting
SFP substantially decreased. Therefore, the Ang II concentration
was lowered to iO M and TGF responses were assessed with-
out and with coinfusion of 10 M NLA. During PTC infusion of
iO M Ang II at 16 2 nl/min, maximum TGF responses were
still significantly increased (Fig. 2B). Coinfusion of iO M Ang II
with 10 M NLA at 20 nl/min was followed by a major decrease
in resting SFP in 7 of the 12 nephrons studied from 44.1 1.8 to
18.7 5.8 mm Hg (P < 0.01; Mann-Whitney U-test). In these
nephrons, the PTC infusion rate was decreased until resting SFP
had recovered to baseline values. When i03 M NLA was
coinfused with io M Ang II at an average rate of 15 3 nl/min,
TGF responses significantly exceeded the responses obtained
during PTC infusion of either Ang II or NLA alone, in the
absence of a significant change in resting SFP (Fig. 2C).
PTC infusion of NLA following systemic losartan administration
In rats maintained on a low sodium diet and administered
losartan, resting SFP averaged 40.2 1.5 mm Hg. Losartan
administration lowered mean arterial pressure (from 137 2 to
109 7; P < 0.01) and caused a strong attenuation of TGF
responsiveness (1.6 0.6 vs. 9.0 0.8 mm Hg in untreated rats;
F < 0.01). PTC infusion of i0— M NLA slightly increased
maximum TGF responses (Fig. 3; P < 0.05 vs. control response).
The increase in TGF responsiveness was significantly less than
observed in untreated rats (P < 0.01).
0 40 0 0 40 0 0
B PTCAn91O-7M16 nI/mm
LSFPM( = 7.5 1.0 LSFPMI = 12.1 2.4a
0 40 0 0 40 0 0
Intraluminal perfusion rate
ni/mm
Fig. 2. Average maximum stop-flow pressure (SFP) feedback responses
under control conditions (first responses) and during peritubular capillary
(PTC) infusion of 10-6 M Ang II (A) and i0 M Ang II (B) and during
combined infusion of 10 M Ang II and lO M NLA (C). ASFPMAX,
maximum TUF-mediated decrease in SFP. P < 0.01 versus first response,
b P < 0.01 versus SFPMAX during PTC i0 M Ang II, P < 0.01 versus
LSFPMAX PTC 10-6 and iO M Ang II.
Intraluminal administration of Ang II, losartan and NLA
Time-control experiments performed in this series of rats
showed a first control response with ATF of 8.8 1.7 mm Hg and
a second response of 10.0 1.6 mm Hg, values that were not
significantly different. As demonstrated previously [41, late prox-
imal perfusion with 10 M NLA was accompanied by a significant
augmentation of TGF responses (Table 1). Following cessation of
the flow to the macula densa, SFP recovered to a value that was
not significantly different from the other values for resting SFP.
Intraluminal application of losartan in dosages of i0— M and
A
50 —
I PIG NLA, 20 nI/mm I
!C/) 30 SFPM = 5.6 0.05 LSFPM( = 12.0 1.7
25
20 I I I
0 40 0 0 40 0 0
Late proximal perfusion rate, ni/mm
Fig. 1. Maximum stop-flow pressure (SFP) feedback responses prior to (first
response) and during (second response) peritubular capilla,y (PTC) infusion
of io M NLA (NLA). LSFPMAX, maximum TGF-mediated decrease in
SFP. a P < 0.01 versus control response (N = 14 nephrons in 8 rats).
PTCAng 10AM
10 nI/mm
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# Nephrons/
Control response Test solution response
Resting Resting
# rats SF1' SFPMAX SFP SFPMAX
ATF 10/6 47.1 1.6 —8.8 1.7 46.5 1.5 —10.0 1.6
NLA, 12/8 46.6 1.5 —6.4 0.7 46.6 1.4 —15.3 1.5iO M
Los, 10/6 46.8 1.8 —7.8 0.9 46.7 1.6 —8.8 0.9io M
Los, 8/4 46.1 1.8 —10.6 1.9 45.0 1.6 —9.6 1.4iO M
Ang II, 9/6 45,4 1.5 —6.6 0.7 45.2 1.6 —6.8 0.9
10_6 M
i0 M neither affected the magnitude of the maximum TGF-
mediated decreases in SFP, nor resting SFP following recovery
from the late proximal perfusion (Table 1). Intraluminal applica-
tion of 10_6 M Ang II failed to induce enhancement of the
maximum-responses (Table 1).
Discussion
The present study was designed to obtain insight in the inter-
action between NO and Ang II in modulating TGF responsive-
ness. Infusion of io M NLA into the peritubular capillaries
substantially augmented maximum TGF-mediated decreases in
SFP. Peritubular infusion of Ang II increased maximum TGF
responses similar as demonstrated previously [31. Concomitant
infusion of Ang II and NLA at a rate that did not affect resting
SFP greatly enhanced TGF responses. In animals administered
the AT1 antagonist losartan, TGF responses were greatly attenu-
ated and PTC administration of NLA failed to enhance TGF
responses to the same extent as in untreated rats. Intraluminal
—25
—30
Syst. Los Control PTC Angil
Fig. 4. Summaiy of maximum SFP feedback responses (isSFPMAX) without
•) and during (LII) peritubular capillaty (PTC) infusion of NLA in nephrons
of animals administered losartan (Syst. Los), of animals maintained on the
regular sodium diet (Control), and in nephrons under the influence of high
local Ang II levels induced by PTC infusion of Ang II (PTC Ang II). P <
0.05 versus Syst. Los with PTC NLA; b P < 0.05 versus Control without
PTC NLA; P < 0.05 versus Control without PTC NLA; dp < 0.05 versus
Control with PTC NLA, P < 0.05 versus PTC Ang II without PTC NLA.
administration of NLA also resulted in enhancement of maximum
TGF responses, however, infusion of losartan and Ang II into the
late proximal tubular lumen failed to affect TGF responses.
The first question was whether the control of NO on glomerular
pressure and TGF responsiveness varies with the prevailing Ang
II levels. Peritubular infusion of NLA augmented maximum
TGF-mediated decreases in SFP, as has been reported previously
[6]. The time-dependent increase in maximum TGF responses as
observed during intraluminal administration of NLA [4] was not
observed during PTC infusion of NLA. Similar to previous reports
[3], infusion of 106 and io M Ang II into the peritubular
capillaries at a rate that did not decrease resting SFP, augmented
maximum TGF responses. In subsequent experiments, PTC infu-
sion of iO M Ang II together with NLA at a rate that did not
affect resting SFP, were associated with extremely high maximum
TGF responses of approximately 24 mm Hg. Thus, during NO
synthesis inhibition and a concomitant increase in local Ang II
levels, extremely high TGF responses were observed. Although
SNGFR responses were not addressed in the present study, it has
been demonstrated that peritubular administration of Ang II [141
increases both feedback-mediated SFP and late proximal flow
responses. Similarly, during intraluminal administration of NLA,
feedback-mediated decreases in both SFP and early proximal flow
rate were enhanced [5].
Systemic pretreatment with the AT1 receptor antagonist, losar-
tan, greatly reduced maximum TGF response, which is in agree-
ment with previous observations [2]. In this situation, the augmen-
tation of TGF responsiveness observed during PTC infusion of
NLA was greatly attenuated as compared to untreated rats.
Figure 4 summarizes the maximum SFP feedback responses
without and during PTC infusion of NLA in nephrons of animals
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Late proximal perfusion rate, ni/mm
Fig. 3. Maximum stop-flow pressure (SFP) feedback responses prior to (first
response) and during (second response) peritubular capillaiy (PTC) infusion
of 10-' M NL.4 (NI.A) in rats treated with losartan. SFPMAX, maximum
TGF-mediated decrease in SFP. P < 0.05 versus control response. 10
nephrons in 4 rats.
Table 1. Maximum TGF-mediated decreases in SFP during late
proximal perfusion with artificial tubular fluid (ATF), N°-L-arginine




P Z 0.01 vs. control response
The control response was always obtained with artificial tubular fluid
and the test solution response during perfusion with ATF or the test
solution.
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sodium diet, and in nephrons under the influence of high local
Ang II levels induced by PTC infusion of Ang II. Under condi-
tions of AT1 receptor blockade with losartan, NO blockade does
not substantially alter the control of the TGF system over
filtration pressure. However, during inhibition of NO formation in
rats under conditions of high local Ang II levels, a large part of the
filtration pressure is under control of the TGF system. As can be
appreciated from this figure, the effects of NO synthesis inhibition
on TGF responsiveness vary directly with the prevailing Ang II
activity.
Several other reports have focused on the interaction between
Ang II and NO in preparations where the TGF system is
operating. In the juxtamedullary nephron preparation, which has
a functional TGF system [15], Ohishi et al demonstrated attenu-
ation of the afl'erent vasoconstriction elicited by NLA in kidneys
pretreated with losartan or enalaprilat [10]. Another study re-
ported that the decrease in GFR and RBF following NLA
infusion was attenuated in animals treated with losartan [16].
Furthermore, it was recently demonstrated that the hypertension
induced by chronic administration of the NOS blocker, L-NAME,
could be prevented by losartan [17]. Finally, Baylis, Harvey and
Engels recently reported that the vasoconstriction observed in
conscious rats during angiotensin infusion is amplified by concom-
itant NO synthase inhibition [18]. These data are in accordance
with the present finding that the tonic influence of NO on the
TGF system largely depends upon the Ang II activity. Of note is
that the renin-angiotensin system in a conscious rat has been
demonstrated not to be activated. As a consequence, the present
findings cannot be extrapolated without caution to a conscious
animal in a resting physiological condition, but merely indicates a
potential interaction which may well occur under conditions
where the physiological balance between Ang II activity and NO
synthesis is disrupted.
Of note are the effects of NO synthesis inhibition on resting
SFP, under conditions of normal and increased Ang II activity.
Peritubular application of NLA did not affect SFP under condi-
tions of zero flow to the macula densa. Wilcox et al have reported
decreases in zero-flow SFP of —1 mm Hg during peritubular
application of L-NMMA [6], which is in close agreement with the
present finding. It has been reported that in vitro perfused afferent
[8, 10, 19, 201 and efferent arterioles [9, 10] can both respond with
a vasoconstriction upon NOS inhibition. In vivo micropuncture
studies employing intravenous and intrarenal infusion of NOS
inhibitors have indicated both predominant afferent [21] and
efferent vasoconstriction [21]. However, arterial pressure in-
creased in both studies so that autoregulatory adjustments on top
of the effects of NOS blockade can be anticipated. The absence of
a change in SFP during local inhibition of NO formation in the
present study suggests that, at least under control conditions, the
preglomerular and postglomerular vasculature constricted to a
similar extent.
Concomitant peritubular infusion of NLA and Ang II resulted
in major decreases in SFP, in the absence of flow to the macula
densa. This indicates that under conditions of high prevailing Ang
II levels, NO synthesis inhibition can cause predominant afferent
vasoconstriction that does not require the actions of the TGF
transmitter. This observation is consistent with data obtained in
the isolated perfused glomerulus, in which NOS-blockade aug-
mented Ang II constriction of the afferent but not the efferent
arteriole [9] and indicates that, besides the actions of Ang II to
enhance TGF responses, NO synthesis inhibition increases the
direct vasoconstrictive actions of Ang II on the afferent arteriole.
The second question concerned a potential interaction of NO
and Ang II on the TGF system from the lumen. Intraluminal
infusion of NO synthesis blockers has been reported to augment
TGF responses [4, 6, 7, 22], which was confirmed in the present
study. It has been proposed that NOS inhibitors affected the TGF
system by blocking the constitutive NOS within macula densa [6,
22]. The presence of high levels of Ang II in proximal tubular fluid
[11, 12] prompted us to determine whether intraluminal Ang II
also influences the TGF system and whether a similar interaction
between intraluminal NO and Ang II on TGF could be demon-
strated. However, administration of high dosages of Ang II and
the AT1 receptor blocker losartan did not significantly affect TGF
responses, which indicates that luminal Ang II is unable to alter
TGF responses. As a consequence, it is considered unlikely that
NO and Ang II interact from the lumen on the macula densa. The
afferent arteriole can be considered as the other potential site of
interaction of the two systems. Unfortunately, the present in vivo
micropunture setting does not allow a further discrimination of
the potential sides of interaction, because infusion of NO and
NOS inhibitors infused into the proximal tubular lumen are likely
to reach both structures [I.
The main conclusion derived from the present findings is that
the influence of NO on the preglomerular vasculature and the
TGF system varies directly with the Ang II activity and counter-
acts both the TGF-dependent and independent actions of Ang II
on the afferent arteriole. Consequently, local NO synthesis phys-
iologically antagonizes the actions of Ang II and responds mo-
mentarily to changes in local Ang II concentration, since in-
creased NO dependency of the TGF system was demonstrated
immediately following peritubular infusion of Ang II. In view of
the high responses during combined PTC infusion of NLA and
Ang II, Ang II directly or indirectly strongly dampens its own
actions by induction of local NO release. This concept has clear
implications for the understanding of hypertensinogenic condi-
tions where the balance between the Ang II formation and NO
activity is disrupted.
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